share_log

This Insider Has Just Sold Shares In Avanos Medical

This Insider Has Just Sold Shares In Avanos Medical

這位內部人士剛剛出售了Avanos Medical的股票
Simply Wall St ·  03/17 10:03

Anyone interested in Avanos Medical, Inc. (NYSE:AVNS) should probably be aware that the Senior VP, Michael Greiner, recently divested US$153k worth of shares in the company, at an average price of US$19.12 each. The eyebrow raising move amounted to a reduction of 15% in their holding.

任何對阿瓦諾斯醫療公司(紐約證券交易所代碼:AVNS)感興趣的人都應該知道,高級副總裁邁克爾·格雷納最近以每股19.12美元的平均價格剝離了該公司價值15.3萬美元的股份。令人驚訝的舉動使他們的持股量減少了15%。

The Last 12 Months Of Insider Transactions At Avanos Medical

Avanos Medical 過去 12 個月的內幕交易

Notably, that recent sale by Michael Greiner is the biggest insider sale of Avanos Medical shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$19.09. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

值得注意的是,邁克爾·格雷納最近的出售是我們去年對Avanos Medical股票的最大一次內幕出售。因此,我們知道一位內部人士以目前的19.09美元左右的股價出售了股票。雖然我們通常不喜歡看到內幕銷售,但更令人擔憂的是是否以較低的價格進行銷售。在這種情況下,大甩賣是在當前價格左右進行的,因此還不錯(但仍然不是積極的)。

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

您可以看到下圖所示的去年的內幕交易(公司和個人)。如果你想確切地知道誰賣了,賣了多少錢,什麼時候賣了,只需點擊下面的圖表即可!

insider-trading-volume
NYSE:AVNS Insider Trading Volume March 17th 2024
紐約證券交易所:AVNS 內幕交易量 2024 年 3 月 17 日

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。

Insider Ownership Of Avanos Medical

Avanos Medical的內部所有權

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Avanos Medical insiders own 1.3% of the company, worth about US$11m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

許多投資者喜歡查看公司內部人士擁有多少股份。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。看來阿瓦諾斯醫療內部人士擁有該公司1.3%的股份,價值約1100萬美元。當然,我們在其他地方看到了更高的內部所有權水平,但這些持股足以表明內部人士與其他股東之間的一致性。

So What Do The Avanos Medical Insider Transactions Indicate?

那麼,阿瓦諾斯醫療內幕交易表明了什麼呢?

Unfortunately, there has been more insider selling of Avanos Medical stock, than buying, in the last three months. Zooming out, the longer term picture doesn't give us much comfort. While insiders do own shares, they don't own a heap, and they have been selling. We're in no rush to buy! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 1 warning sign with Avanos Medical and understanding it should be part of your investment process.

不幸的是,在過去的三個月中,Avanos Medical股票的內幕拋售多於買入的股票。放大一點,長遠的畫面並不能給我們帶來太大的安慰。儘管內部人士確實擁有股票,但他們並不擁有大量股票,他們一直在拋售。我們並不急於購買!因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。在投資風險方面,我們已經向Avanos Medical確定了一個警告信號,並知道這應該是您投資過程的一部分。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論